Actively Recruiting
Evaluation of Nanosecond Pulsed Field Ablation for Treating T1N0M0 Papillary Thyroid Carcinoma Using the CellFX System
Led by M.D. Anderson Cancer Center · Updated on 2026-09-11
15
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of nanosecond pulsed field ablation nsPFA in treating patients with T1N0M0 papillary thyroid carcinoma PTC, a type of thyroid cancer. The study aims to measure changes in thyroid nodule volume, including volume reduction rate, technique efficacy, and nodule regrowth after the procedure. The research also assesses clinical safety, possible complications, and changes in ultrasound features and health-related quality of life over time. Participants will undergo an outpatient thyroid ablation using the CellFX nsPFA Percutaneous Electrode System. This procedure is performed under local anesthesia or intravenous sedation. The study involves a single treatment group receiving this device-based intervention to evaluate its impact on the thyroid nodules. Throughout the study, participants will have follow-up visits to monitor thyroid nodule volume changes and safety outcomes, including adverse events, for about one year on average. Researchers will use ultrasound evaluations and clinical assessments to track treatment effects and quality of life. The total study duration extends up to the study completion date, with ongoing monitoring as part of the follow-up period.
CONDITIONS
Brief Title
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
Research Team
V
Victoria E Banuchi, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here